✦ LIBER ✦

Late cerebrovascular complications of radiation therapy for pediatric primary central nervous system tumors

✍ Scribed by Passos, J.; Nzwalo, H.; Marques, J.; Azevedo, A.; Nunes, S.; Salgado, D.

Book ID: 123330922
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 71 KB
Volume: 333
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2013.07.929

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiation therapy for histologically con

Radiation therapy for histologically confirmed primary central nervous system germinoma

✍ Michael G. Haddock; Steven E. Schild; Bernd W. Scheithauer; Paula J. Schomberg 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 1018 KB

Radiation therapy of tumors of the centr

Radiation therapy of tumors of the central nervous system in childhood

✍ Glenn E. Sheline 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 581 KB

Primary central nervous system lymphoma

Primary central nervous system lymphoma in AIDS. Results of radiation therapy

✍ Silvia C. Formenti; Parkash S. Gill; Eva Lean; Mark Rarick; Paul R. Meyer; Willi 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 691 KB

Tumors of the Central Nervous System, Vo

Tumors of the Central Nervous System, Volume 5 || Nanotechnology-Based Therapy for Malignant Tumors of the Central Nervous System

✍ Hayat, M.A. 📂 Article 📅 2011 🏛 Springer Netherlands ⚖ 286 KB

Proton Radiation Therapy for Pediatric C

Proton Radiation Therapy for Pediatric Central Nervous System Ependymoma: Clinical Outcomes for 70 patients

✍ Sethi, R.; Yeap, B.Y.; Marino, R.; Marcus, K.J.; Caruso, P.; Pulsifer, M.B.; Ebb 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Phase II evaluation of topotecan for ped

Phase II evaluation of topotecan for pediatric central nervous system tumors

✍ Susan M. Blaney; Peter C. Phillips; Roger J. Packer; Richard L. Heideman; Stacey 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 473 KB 👁 2 views

## BACKGROUND. Topotecan is a topoisomerase I inhibitor that has good penetration across the blood-brain barrier and significant antitumor activity against human brain tumor xenografts. In a Phase I trial in children with refractory cancer, topotecan was well tolerated when administered as a 24-ho